

CITATION REPORT

List of articles citing

Safety of COVID-19 Vaccination in US Children Ages 5-11 Years.

DOI: 10.1542/peds.2022-057313
Pediatrics, 2022, , .

Source: <https://exaly.com/paper-pdf/145945554/citation-report.pdf>

Version: 2024-04-11

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
26	COVID-19 Vaccines: Safe and Effective in Children Ages 5-11 Years.. <i>Pediatrics</i> , 2022 ,	7.4	0
25	Pfizer-BioNTech COVID-19 vaccine safe in children. <i>Reactions Weekly</i> , 2022 , 1908, 11-11	0	6
24	Interim Recommendations of the Advisory Committee on Immunization Practices for Use of Moderna and Pfizer-BioNTech COVID-19 Vaccines in Children Aged 6 Months-5 Years United States, June 2022. <i>Morbidity and Mortality Weekly Report</i> , 2022 , 71, 859-868	31.7	3
23	COVID-19 vaccination for children aged 5-11 years. <i>Lancet, The</i> , 2022 , 400, 74-76	40	2
22	Cross-Sectional Survey on BNT162b2 mRNA COVID-19 Vaccine Serious Adverse Events in Children 5 to 11 Years of Age: A Monocentric Experience. 2022 , 10, 1224		1
21	Safety Monitoring of Pfizer-BioNTech COVID-19 Vaccine Booster Doses Among Children Aged 5-11 Years United States, May 17-July 31, 2022. 2022 , 71, 1047-1051		2
20	Major severe acute respiratory coronavirus-2 (SARS-CoV-2) vaccine-associated adverse effects; benefits outweigh the risks. 1-18		0
19	Time course of adverse reactions after BNT162b2 vaccination in healthy and allergic disease individuals aged 5-11 years: an observational and historical cohort study.		
18	SARS-CoV-2 infection in pediatric population before and during the Delta (B.1.617.2) and Omicron (B.1.1.529) variants era. 2022 , 19,		5
17	Time course of adverse reactions following BNT162b2 vaccination in healthy and allergic disease individuals aged 5-11 years and comparison with individuals aged 12-15 years: an observational and historical cohort study.		0
16	COVID-19 vaccine update: vaccine effectiveness, SARS-CoV-2 variants, boosters, adverse effects, and immune correlates of protection. 2022 , 29,		5
15	Adverse events of the Pfizer-BioNTech COVID-19 vaccine in Korean children and adolescents aged 5 to 17 years. 2022 , 13, 382-390		0
14	Reactions Following Pfizer-BioNTech COVID-19 mRNA Vaccination and Related Healthcare Encounters Among 7,077 Children Aged 5-11 Years Within an Integrated Healthcare System. 2022 ,		0
13	A highly efficient needle-free-injection delivery system for mRNA-LNP vaccination against SARS-CoV-2. 2023 , 48, 101730		1
12	Assessment of Efficacy and Safety of mRNA COVID-19 Vaccines in Children Aged 5 to 11 Years.		0
11	A Cross-Sectional Study to Assess mRNA-COVID-19 Vaccine Safety among Indian Children (5-17 Years) Living in Saudi Arabia. 2023 , 11, 207		0
10	COVID-19 Vaccination in Pediatrics: Was It Valuable and Successful?. 2023 , 11, 214		0

- 9 Short term adverse event profile of COVID-19 mRNA vaccines in children aged 5–15 years in Australia. **2023**, 31, 100684 ○
- 8 Immunogenicity, effectiveness, and safety of COVID-19 vaccines among children and adolescents aged 2–18 years: an updated systematic review and meta-analysis. ○
- 7 Safety Monitoring of mRNA COVID-19 Vaccines in Children Aged 5 to 11 Years by Using EudraVigilance Pharmacovigilance Database: The CoVaxChild Study. **2023**, 11, 401 ○
- 6 Live-virus neutralization of the omicron variant in children and adults 14 months after SARS-CoV-2 wild-type infection. **2023**, 95, ○
- 5 Anaphylaxis rates following mRNA COVID-19 vaccination in children and adolescents: Analysis of data reported to EudraVigilance. **2023**, 41, 2382-2386 ○
- 4 Letter by Donzelli Regarding Article, Risk of Myocarditis After Sequential Doses of COVID-19 Vaccine and SARS-CoV-2 Infection by Age and Sex **2023**, 147, ○
- 3 Effectiveness of BNT162b2 and CoronaVac vaccines against omicron in children aged 5 to 11 years. ○
- 2 Batch-dependent safety of the BNT162b2 mRNA COVID-19 vaccine. ○
- 1 Safety and effectiveness of vaccines against COVID-19 in children aged 5–11 years: a systematic review and meta-analysis. **2023**, ○